Recently Featured

Abridge CTO Discusses Competitive Landscape with Epic and Future Innovations

February 14, 2026
Abridge has emerged as a significant player in the healthcare AI sector, boasting a multi-billion dollar valuation and a widely adopted ambient scribe technology utilized by numerous health systems. As the company continues to expand, questions about its future direction and competitive strategies arise, particularly in relation to industry giant Epic. In a recent interview,…

FDA Rejects Regenxbio Treatment in Another Blow to Gene Therapy

February 13, 2026
The FDA has officially rejected Regenxbio’s gene therapy treatment, marking a significant setback for the company and the broader gene therapy landscape. This decision follows closely on the heels of the agency’s recent suspension of clinical trials due to emerging safety concerns, highlighting the ongoing challenges faced by developers in this innovative but precarious field.…

AstraZeneca Aims for $80 Billion Revenue Target by 2030

February 13, 2026
LONDON — AstraZeneca’s CEO Pascal Soriot has set an ambitious goal for the company to achieve $80 billion in annual sales by 2030. This target, announced in 2024, reflects a significant escalation in the company’s growth strategy, particularly following a period of robust performance driven by its COVID-19 vaccine and oncology portfolio. The pharmaceutical giant…

AstraZeneca bets on continued oncology demand for 2026 growth

February 13, 2026
AstraZeneca’s cancer medicine sales surged by 14% in 2025, signaling a robust demand in the oncology sector that the company anticipates will continue into 2026. This growth is underpinned by the company’s strategic focus on expanding its oncology portfolio, particularly through the introduction of new therapies targeting various malignancies. With several promising drug candidates in…

Ongoing Cases